Alliance pharmaceutique pancanadienne (APP) – dernières mises à jour

État Nombre total Résumé
En négociation 45 Non liées à l’oncologie : 29
Liées à l’oncologie : 16
Négociations envisagées 12 Non liées à l’oncologie : 8
Liées à l’oncologie : 4
Négociations terminées 786 Avec lettre d’intention : 679
Sans entente : 107
Négociations qui n’ont pas eu lieu 108

Activités de l’APP dans les quatre dernières semaines

Marque Fabricant Indication Date d’engagement
Ebglyss Eli Lilly Canada Inc. Atopic dermatitis
Zilbrysq UCB Canada Inc. Generalized myasthenia gravis (gMG)
Leqvio Novartis Pharmaceuticals Canada Inc. Primary hypercholesterolemia (non-familial and heterozygous familial)
Winrevair Merck Canada Inc. Pulmonary Arterial Hypertension (WHO group 1)
Vyloy Astellas Pharma Inc. In combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal
Leqvio Novartis Pharmaceuticals Canada Inc. Primary hypercholesterolemia
Ofev Boehringer Ingelheim (Canada) Ltd. Idiopathic pulmonary fibrosis and PF-ILD
Ojjaara GlaxoSmithKline Inc. For the treatment of splenomegaly and/or disease-related symptoms, in adult patients with intermediate or high-risk primary myelofibrosis (MF), post polycythemia vera myelofibrosis or post essential thrombocythemia MF who have moderate to severe anemia.

Négociations achevées dans les quatre dernières semaines avec une lettre d’intention

Marque Fabricant Indication Date d’engagement Date d’achèvement
Nextstellis Searchlight Pharma Inc. Prevention of Pregnancy
Trodelvy Gilead Sciences Canada Inc. Breast cancer, unresectable locally advanced or metastatic, HR-positive, HER2-negative (IHC 0, IHC 1+, or IHC 2+/ISH-) in adult patients who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting
Tecvayli Janssen Inc. Multiple myeloma, relapsed or refractory, in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progre
Cabtreo Bausch Health, Canada Inc. Acne Vulgaris
Xcopri Paladin Labs Inc. Epilepsy, partial-onset seizures

Négociations achevées dans les quatre dernières semaines sans entente

Marque Fabricant Indication Date d’engagement Date d’achèvement
Beqvez Pfizer Canada ULC Hemophilia B (congenital Factor IX deficiency) in adults (aged 18 years or older), moderately severe to severe, who are negative for neutralizing antibodies to variant AAV serotype Rh74
Elrexfio Pfizer Canada ULC Multiple myeloma, relapsed or refractory, in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progre

Négociations que l’APP a décidé de ne pas entreprendre dans les quatre dernières semaines